Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

New phase Ib/IIa study evaluates VB-119 in membranous nephropathy

May 18, 2021

Dosing initiates in phase I study of GFB-024 in severe insulin-resistant diabetic nephropathy

May 14, 2021

Nephraegis Therapeutics to develop NPH-022 for the prevention and treatment of AKI

May 13, 2021

Phase III FIGARO-DKD cardiovascular outcomes study of finerenone meets primary endpoint

May 10, 2021

Benlysta approved in E.U. for active lupus nephritis

May 6, 2021

European Commission approves Sibnayal for distal renal tubular acidosis

May 5, 2021

Topline data presented from first cohort of phase Ib trial of RGLS-4326

May 4, 2021

FDA approves Farxiga for chronic kidney disease

May 3, 2021

Pooled data from the AURORA and AURA-LV trials across lupus nephritis biopsy classes

April 12, 2021

X-Chem discloses new HAOX1 inhibitors

April 8, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...